Gravar-mail: Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma
The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study